PARP Cancer Research Results

PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
2838- FIS,    Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2)
cl‑Casp3↑, cl‑PARP↑, MMP↓, Cyt‑c↑, ROS↑, NRF2↓,
2842- FIS,    Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells
- in-vitro, GC, AGS
TumCCA↑, CDK2↓, P53↑, selectivity↑, MMP↓, DNAdam↑, cl‑PARP↑, mt-ROS↑, eff↓, survivin↓,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
1086- GA,    Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation
- in-vitro, AML, K562
tumCV↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
1961- GamB,    Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS
- in-vitro, Melanoma, RPMI-8226
TumCG↓, Apoptosis↑, ROS↑, Casp3↑, cl‑PARP↑, SIRT1↓, eff↓,
1966- GamB,  Cisplatin,    Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
- in-vitro, Lung, A549 - in-vitro, Lung, NCIH1299
TumCCA↑, PARP↑, eff↑, ROS↑, ChemoSen↑,
1967- GamB,    Gambogic acid induces apoptotic cell death in T98G glioma cells
- in-vitro, GBM, T98G
BAX↑, AIF↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↓, Bcl-2↓, ROS↑,
810- GAR,  GEM,    Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- in-vitro, PC, NA
TumCP↓, Apoptosis↑, PARP↝, VEGF↝, MMPs↝, Casp↝, NF-kB↝, miR-21↝,
820- GAR,    Garcinol in gastrointestinal cancer prevention: recent advances and future prospects
- Review, NA, NA
Fas↑, TRAIL↑, PARP↑, BAX↑, Bcl-2↓, ROS↑, STAT3↓, Apoptosis↑, MMP2↓, MMP9↓,
821- GAR,    Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis
- in-vitro, Liver, Hep3B
ROS↑, CHOP↑, MMP↓, Bax:Bcl2↑, Casp8↑, Casp3↑, Casp9↑, cl‑PARP↑, DFF45↑,
831- GAR,  CUR,    Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells
- in-vitro, AML, HL-60
Apoptosis↑, Casp3↑, MMP↓, Cyt‑c↑, proCasp9↑, Bcl-2↓, BAX↑, PARP↓, DNAdam↑, DFF45↓,
828- GAR,  Cisplatin,    Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells
- in-vitro, Ovarian, OVCAR-3
tumCV↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, p‑PI3K↓, p‑Akt↓, NF-kB↓,
795- GAR,    Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug
- Review, NA, NA
HATs↓, BAX↑, PARP↑, Bcl-2↓, Casp3↑, Casp9↑, DR5↑, cFLIP↓, MMP2↓, MMP9↓, STAT3↓, p‑Akt↓,
843- Gra,    Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling
- in-vitro, NMSC, A431 - in-vitro, NMSC, UW-BCC1 - in-vitro, Nor, NHEKn
TumCG↓, TumCCA↑, Cyc↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, Sufu↑, BAX↑, Bcl-2↓, *toxicity↓,
1657- HCAs,    Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023
- in-vitro, CRC, HT-29
cl‑Casp3↑, BAX↑, cl‑PARP↑, γH2AX↑, Cyt‑c↑,
1912- HCQ,  TMZ,    Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy
- in-vivo, GBM, U87MG
LC3B-II↑, CHOP↑, cl‑PARP↑,
1286- HNK,    The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
- in-vitro, CLL, NA
Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-2↓, BAX↑,
1154- HNK,  MET,    Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin
- in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
cl‑PARP↑, Bcl-2↓, ERα/ESR1↓,
2073- HNK,    Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo
- in-vitro, OS, U2OS - in-vivo, NA, NA
TumCD↑, TumAuto↑, Apoptosis↑, TumCCA↑, GRP78/BiP↑, ROS↑, eff↓, p‑ERK↑, selectivity↑, Ca+2↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, LC3B-II↑, ATG5↑, TumVol↓, TumW↓, ER Stress↑,
2867- HNK,    Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway
- in-vitro, Nor, C2C12
*antiOx↑, *ROS↓, *Bcl-2↑, *BAX↓, Casp9∅, Casp3∅, cl‑PARP∅, Cyt‑c?,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
4639- HT,    Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, p27↑, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, p‑Akt↓, p‑STAT3↓, NF-kB↓, AR↓, ROS↑, *BioAv↓, *toxicity∅,
1918- JG,    ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro
- in-vitro, Liver, HepG2 - in-vivo, NA, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑, toxicity↝, p62↓, DR5↑, Casp8↑, PARP↑, cl‑Casp3↑,
5114- JG,    Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism
- in-vitro, AML, HL-60
ROS↑, GSH↓, eff↓, cl‑PARP↑, proCasp3↑, proCasp9↑, MMP↓, Cyt‑c↑, Diablo↑,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
4786- Lyco,    Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3
TumCP↓, TumCCA↑, cl‑PARP↑, ERK↑, cycD1/CCND1↓, P21↓, p‑Akt↓, mTOR↓, BAX↑, AntiCan↑, Risk↓,
2533- M-Blu,  PDT,    Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells
- in-vitro, Lung, A549
MMP↓, p‑MAPK↑, ROS↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, eff↓,
4537- MAG,    Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action
- in-vivo, Melanoma, NA - in-vitro, Melanoma, A431
*cl‑Casp8↑, *PARP↑, *P21↑, tumCV↓, TumCP↓, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK4↓, CDC2↓, P21↑, Apoptosis↑,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
3486- MF,    Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death
- in-vitro, NA, NA
ChemoSen↑, tumCV↓, cl‑PARP↑, Casp7↑, Casp9↑, survivin↓, BAX↑, DNAdam↑, ROS↑, eff↓,
496- MF,    Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, ZR-75-1 - in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231
ROS↑, PI3K↓, Akt↓, GSK‐3β↑, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, CycB/CCNB1↓, TumCCA↑, p‑Akt↓, TumCP↓, selectivity↑, eff↓,
4353- MF,  Chemo,    Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCCA↑, Apoptosis↑, eff↑, TumCCA↑, Casp↝, p‑CDK2↓, cycE/CCNE↓, Fas↑, BAX↑, survivin↓, Mcl-1↓, cl‑PARP↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑,
1128- Myr,    Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer
- vitro+vivo, Ovarian, NA
MAPK↓, ERK↓, PI3K↓, Akt↓, p‑PARP↑, cl‑Casp3↑, Bax:Bcl2↑, TumCMig↓, SMAD3↓,
4976- Nimb,    Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition
- vitro+vivo, PC, NA
ROS↑, Apoptosis↑, TumAuto↑, TumCP↓, TumCMig↓, TumCI↓, EMT↓, Dose↓, selectivity↑, Akt↓, eff↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓,
4977- Nimb,    Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis
- vitro+vivo, PC, AsPC-1 - in-vitro, PC, PANC1
SOD2↑, TumCG↓, TumMeta↓, ROS↑, Apoptosis↑, PI3K↓, Akt↓, EMT↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, Bcl-2↓,
150- NRF,  CUR,  docx,    Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
- in-vitro, Pca, C4-2B
p‑Akt↓, p‑eIF2α↑, ER Stress↑, ATF4↑, CHOP↑, TRIB3↑, ChemoSen↑, Casp3↑, cl‑PARP↑, BID↑, XBP-1↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
2057- PB,    Trichomonas vaginalis induces apoptosis via ROS and ER stress response through ER–mitochondria crosstalk in SiHa cells
- in-vitro, Cerv, SiHa
ROS↓, tumCV∅, cl‑PARP↓, cl‑Casp3↓, MMP∅, ER Stress↓,
2070- PB,    Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells
- in-vitro, CRC, HT-29
TumCG↓, Apoptosis↑, MMP↓, Casp3↑, PARP↓, NF-kB↓, eff↑,
1674- PBG,  SDT,  HPT,    Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells
- in-vitro, PC, PANC1 - in-vitro, Nor, H6c7
tumCV↓, ROS↑, eff↑, Dose∅, selectivity↑, MMP↓, mtDam↑, cl‑PARP↑, p‑ERK↓, p‑JNK↑, p‑p38↑, eff↓, ChemoSen↑,
1676- PBG,    Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies
- Review, Var, NA
ROS↑, MMP↓, Bcl-2↓, eff↑, tumCV↓, TumCCA↑, angioG↓, PAK1↓, HDAC1↓, HDAC2↓, P53↑, PCNA↓, cycD1/CCND1↓, cycE/CCNE↓, P21?, BAX↑, cl‑Casp3↑, cl‑PARP↑, ChemoSen↑,
1682- PBG,    Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits
- Review, Var, NA
i-LDH↓, Akt↓, MAPK↓, NF-kB↓, IL1β↓, IL6↓, TNF-α↓, iNOS↓, COX2↓, ROS↓, Bcl-2↓, PARP↓, P53↑, BAX↑, Casp3↑, TumCCA↑, Cyt‑c↑, MMP↓, eff↑,

Showing Research Papers: 151 to 200 of 285
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 285

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↓, 2,   Catalase↑, 1,   CYP1A1↓, 1,   GPx↓, 1,   GPx↑, 2,   GSH↓, 3,   GSH↑, 1,   GSR↓, 1,   GSR↑, 1,   GSTA1↑, 1,   GSTs↓, 1,   H2O2↑, 1,   HO-1↓, 2,   Keap1↓, 1,   NOX4↑, 1,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 3,   ROS↓, 4,   ROS↑, 25,   mt-ROS↑, 1,   SIRT3↓, 1,   SIRT3↑, 1,   SOD↓, 1,   SOD↑, 1,   SOD2↓, 2,   SOD2↑, 1,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 3,   CDC2↓, 2,   MMP↓, 15,   MMP∅, 1,   mtDam↑, 2,   c-Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 4,   p‑AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 3,   p‑cMyc↑, 1,   FASN↓, 2,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   i-LDH↓, 1,   LDHA↓, 1,   PKM2↓, 3,   PPARγ↑, 2,   SIRT1↓, 3,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 12,   p‑Akt↓, 7,   APAF1↑, 1,   Apoptosis↑, 21,   BAD↑, 1,   Bak↑, 2,   BAX↓, 1,   BAX↑, 20,   Bax:Bcl2↑, 5,   Bcl-2↓, 19,   Bcl-2↑, 1,   Bcl-xL↓, 2,   BID↑, 2,   BIM↑, 1,   Casp↑, 3,   Casp↝, 2,   Casp1↓, 1,   Casp3↑, 19,   Casp3∅, 1,   cl‑Casp3↓, 1,   cl‑Casp3↑, 12,   proCasp3↓, 1,   proCasp3↑, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 6,   cl‑Casp8↑, 5,   Casp9↑, 11,   Casp9∅, 1,   cl‑Casp9↑, 3,   proCasp9↑, 2,   cFLIP↓, 1,   Chk2↓, 1,   Cyt‑c↑, 13,   Cyt‑c?, 1,   Diablo↑, 2,   DR5↑, 5,   FADD↑, 1,   Fas↓, 1,   Fas↑, 3,   FasL↑, 2,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   iNOS↓, 3,   JNK↑, 2,   p‑JNK↑, 2,   MAPK↓, 6,   p‑MAPK↑, 1,   Mcl-1↓, 4,   Mcl-1↑, 1,   MDM2↓, 2,   p‑MDM2↓, 1,   NICD↓, 1,   p27↑, 4,   p‑p38↑, 2,   survivin↓, 7,   Telomerase↓, 1,   TRAIL↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   H3↓, 1,   H3↑, 1,   H4↓, 1,   H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-21↝, 1,   tumCV↓, 8,   tumCV∅, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 5,   cl‑CHOP↑, 1,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↑, 3,   HSF1↓, 1,   HSP27↝, 1,   HSP70/HSPA5↝, 1,   HSP90↓, 1,   IRE1↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 2,   LC3B-II↑, 3,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DFF45↓, 1,   DFF45↑, 1,   DNAdam↓, 1,   DNAdam↑, 9,   P53?, 1,   P53↓, 1,   P53↑, 10,   PARP↓, 5,   PARP↑, 6,   PARP↝, 1,   p‑PARP↑, 1,   cl‑PARP↓, 3,   cl‑PARP↑, 31,   cl‑PARP∅, 1,   proPARP↓, 1,   PCNA↓, 4,   γH2AX↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 6,   p‑CDK2↓, 1,   CDK4↓, 5,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 10,   cycE/CCNE↓, 7,   P21?, 2,   P21↓, 1,   P21↑, 8,   p‑RB1↓, 1,   TumCCA↑, 19,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD34↓, 1,   cFos↓, 2,   cFos↑, 1,   CSCs↓, 1,   EMT↓, 6,   ERK↓, 5,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 2,   HDAC1↓, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HH↓, 1,   IGF-1↓, 1,   mTOR↓, 8,   mTOR↑, 1,   mTORC1↓, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH1↓, 3,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 7,   p‑PI3K↓, 2,   PTEN↓, 1,   PTEN↑, 1,   RAS↓, 2,   Shh↓, 1,   Smo↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   Sufu↑, 1,   TAZ↓, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 5,   Wnt↓, 4,  

Migration ⓘ

AEG1↓, 1,   AP-1↓, 1,   AXL↓, 1,   Ca+2↑, 2,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 2,   FAK↓, 1,   GLI2↓, 1,   ITGB1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 1,   MMP2↓, 8,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 6,   MMPs↓, 1,   MMPs↝, 1,   N-cadherin↓, 2,   PAK1↓, 1,   Rac1↓, 1,   Rho↓, 1,   SMAD3↓, 1,   Snail↓, 1,   SOX4↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TRIB3↑, 1,   TumCI↓, 6,   TumCMig↓, 5,   TumCP↓, 10,   TumMeta↓, 5,   TumMeta↑, 1,   Twist↓, 1,   Tyro3↓, 1,   uPA↓, 1,   Vim↓, 1,   Vim↑, 1,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 4,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   ATF4↑, 2,   EGFR↓, 3,   EGFR↑, 1,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 4,   VEGF↝, 1,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 8,   CXCR4↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IKKα↓, 2,   IL1↑, 1,   IL1β↓, 2,   IL2↑, 2,   IL4↑, 1,   IL6↓, 5,   Inflam↓, 1,   JAK1↓, 2,   JAK2↓, 1,   NF-kB↓, 14,   NF-kB↝, 1,   p‑NF-kB↑, 1,   p65↓, 3,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 5,   TNF-α↓, 4,   TNF-α↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 3,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 7,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 12,   Dose↓, 1,   Dose↝, 2,   Dose∅, 1,   eff↓, 10,   eff↑, 9,   Half-Life↓, 1,   Half-Life↝, 4,   MDR1↓, 1,   RadioS↑, 5,   selectivity↑, 8,  

Clinical Biomarkers ⓘ

AR↓, 3,   CEA↓, 1,   EGFR↓, 3,   EGFR↑, 1,   ERα/ESR1↓, 1,   hTERT/TERT↓, 1,   IL6↓, 5,   i-LDH↓, 1,   NSE↓, 1,   TRIB3↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cachexia↓, 1,   chemoP↑, 2,   OS↑, 1,   Risk↓, 1,   toxicity↓, 1,   toxicity↝, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 339

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 2,   GSTs↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 3,   SOD↑, 2,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Cell Death ⓘ

BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   cl‑Casp8↑, 1,  

DNA Damage & Repair ⓘ

PARP↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   neuroP↑, 1,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 30

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
16 Apigenin (mainly Parsley)
15 Curcumin
14 Thymoquinone
12 Baicalein
12 Quercetin
12 Fisetin
10 Sulforaphane (mainly Broccoli)
8 EGCG (Epigallocatechin Gallate)
8 Shikonin
7 Ashwagandha(Withaferin A)
7 Berberine
7 Capsaicin
6 Boswellia (frankincense)
6 Carnosic acid
6 Garcinol
6 Honokiol
6 Piperlongumine
6 Vitamin C (Ascorbic Acid)
5 Metformin
5 Betulinic acid
5 Chrysin
5 Emodin
5 Silymarin (Milk Thistle) silibinin
4 doxorubicin
4 Bufalin/Huachansu
4 Carvacrol
4 Citric Acid
4 Gambogic Acid
4 Propolis -bee glue
4 Phenethyl isothiocyanate
4 Resveratrol
3 Auranofin
3 Allicin (mainly Garlic)
3 Cisplatin
3 Brucea javanica
3 Thymol-Thymus vulgaris
3 Docetaxel
3 Ellagic acid
3 Magnetic Fields
3 Propyl gallate
2 Silver-NanoParticles
2 5-fluorouracil
2 Artemisinin
2 Berbamine
2 temozolomide
2 brusatol
2 Boron
2 Radiotherapy/Radiation
2 HydroxyTyrosol
2 Juglone
2 Luteolin
2 Lycopene
2 Magnolol
2 Nimbolide
2 Phenylbutyrate
2 Paclitaxel
2 Piperine
2 Rosmarinic acid
2 salinomycin
2 Selenite (Sodium)
2 Ursolic acid
2 Urolithin
1 3-bromopyruvate
1 immunotherapy
1 Atorvastatin
1 Aloe anthraquinones
1 Baicalin
1 almonertinib
1 Bromelain
1 Butyrate
1 Sorafenib (brand name Nexavar)
1 Cat’s Claw
1 Celastrol
1 Chlorogenic acid
1 Chlorophyllin
1 Coenzyme Q10
1 Dichloroacetophenone(2,2-)
1 Dichloroacetate
1 Fucoidan
1 Ferulic acid
1 Gallic acid
1 Gemcitabine (Gemzar)
1 Graviola
1 Hydroxycinnamic-acid
1 hydroxychloroquine
1 lambertianic acid
1 Methylene blue
1 Photodynamic Therapy
1 Chemotherapy
1 Myricetin
1 nelfinavir/Viracept
1 Oleuropein
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 VitK3,menadione
1 Hyperoside
1 Selenium NanoParticles
1 chitosan
1 Folic Acid, Vit B9
1 Osimertinib
1 Adagrasib
1 Aflavin-3,3′-digallate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page